Skip to main content

Lexeo Therapeutics, Inc.

LXEO
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001907108

In the last 90 days, Lexeo Therapeutics, Inc. insiders filed 0 open-market purchases and 3 sales; 141 institutions reported holding it in 13F filings for Q2 2026, worth $410.9M in total; no superinvestor holds it.

Q2 2024 vs. Q1 2024

How the institutions holding Lexeo Therapeutics, Inc. changed between Q1 2024 and Q2 2024.

All holders in Q2 2024All holders in Q1 2024

13F holders of LXEO: Q1 2024 compared with Q2 2024
MeasureQ1 2024Q2 2024Change
Holders5460+6
Shares23.1M26.6M+3.46M (+15.0%)
Value$361.5M$426.3M+$64.7M (+17.9%)

New holders (15)

Institutions that held Lexeo Therapeutics, Inc. at the end of Q2 2024 but not at the end of Q1 2024.

Institutions new to LXEO in Q2 2024
InstitutionSharesValue% of portfolio
Tudor Investment Corp Et Al132,187$2.12M0.02%
Polar Asset Management Partners Inc.65,300$1.05M0.03%
Wellington Management Group LLP22,101$354.5K0.00%
Franklin Resources Inc14,035$225.1K0.00%
Alliancebernstein L.P.10,750$172.4K0.00%
EntryPoint Capital, LLC10,542$169.1K0.08%
Corebridge Financial, Inc.5,507$88.3K0.00%
Mirae Asset Global ETFs Holdings Ltd.4,881$78.3K0.00%
Deutsche Bank AG4,560$73.1K0.00%
ADAR1 Capital Management, LLC1,300$20.9K0.00%
Nisa Investment Advisors, LLC32$5130.00%
GAMMA Investing LLC14$2250.00%
SRS Capital Advisors, Inc.12$1930.00%
Lazard Asset Management LLC33$00.00%
CWM, LLC16$00.00%

Sold out (9)

Institutions that held Lexeo Therapeutics, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.

Institutions that sold out of LXEO in Q2 2024
InstitutionShares, Q1 2024Value, Q1 2024
Cornell University126,258$1.98M
Bank of Montreal111,186$1.75M
Jump Financial, LLC14,894$233.5K
Renaissance Technologies LLC14,576$229.0K
Susquehanna International Group, LLP12,041$188.8K
American International Group, Inc.5,053$79.2K
STRS Ohio1,800$28.0K
Metropolitan Life Insurance Co599$9.39K
Catalyst Funds Management Pty Ltd531$8.33K